Statement: A total of 32 patients in the primary trial had Diarrhoea.
Primary_evidence: Adverse Events 1:   Total: 19/213 (8.92%)   Pancytopenia 0/213 (0.00%)   Anaemia 1/213 (0.47%)   Atrial fibrillation 0/213 (0.00%)   Cardiac failure congestive 0/213 (0.00%)   Myocardial infarction 0/213 (0.00%)   Supraventricular tachycardia 0/213 (0.00%)   Diarrhoea 0/213 (0.00%)   Colitis 0/213 (0.00%)   Vomiting 1/213 (0.47%)   Nausea 1/213 (0.47%)   Enterocolitis 0/213 (0.00%) Adverse Events 2:   Total: 133/416 (31.97%)   Pancytopenia 1/416 (0.24%)   Anaemia 0/416 (0.00%)   Atrial fibrillation 2/416 (0.48%)   Cardiac failure congestive 1/416 (0.24%)   Myocardial infarction 1/416 (0.24%)   Supraventricular tachycardia 1/416 (0.24%)   Diarrhoea 32/416 (7.69%)   Colitis 14/416 (3.37%)   Vomiting 4/416 (0.96%)   Nausea 3/416 (0.72%)   Enterocolitis 2/416 (0.48%)